Champions Oncology (CSBR) Total Liabilities (2011 - 2026)
Champions Oncology (CSBR) posted quarterly Total Liabilities of $22.9 million for Q2 2026, down 19.78% year-over-year from $28.6 million in Q2 2025, and down 4.77% quarter-over-quarter from $24.1 million in Q1 2026.
Champions Oncology (CSBR) Total Liabilities (2011 - 2026) Analysis & Trends
Champions Oncology's Total Liabilities history runs 16 years deep, the most recent figure standing at $22.9 million for Q2 2026.
- In Q2 2026, Total Liabilities fell 19.78% year-over-year to $22.9 million; the TTM figure through Apr 2026 stood at $22.9 million (down 19.78% YoY), while the FY2026 annual figure was $22.9 million, down 19.78% from the prior year.
- Total Liabilities for Q2 2026 stood at $22.9 million, down from $24.1 million in the prior quarter.
- The five-year high for Total Liabilities was $29.7 million in Q2 2023, with the low at $22.9 million in Q2 2026.
- The 5-year median for Total Liabilities is $26.6 million (2022), against an average of $26.6 million.
- The sharpest annual moves came in 2022 and 2026: Total Liabilities jumped 41.77% in 2022, then retreated 19.78% in 2026.
- Champions Oncology's Total Liabilities stood at $27.2 million in 2022, then increased by 3.71% to $28.2 million in 2023, then decreased by 12.91% to $24.6 million in 2024, then increased by 5.59% to $25.9 million in 2025, then decreased by 11.61% to $22.9 million in 2026.
- Business Quant data shows CSBR's Total Liabilities at $22.9 million in Q2 2026, $24.1 million in Q1 2026, and $25.9 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.35 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 10.03 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 3.22 Bn |
| 10 | Champions Oncology | 71.17 Mn | 71.17 Mn | 7.03 Mn | 22.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 30, 2026 | 22.92 Mn |
| Jan 31, 2026 | 24.07 Mn |
| Oct 31, 2025 | 25.93 Mn |
| Jul 31, 2025 | 27.01 Mn |
| Apr 30, 2025 | 28.57 Mn |
| Jan 31, 2025 | 25.16 Mn |
| Oct 31, 2024 | 24.56 Mn |
| Jul 31, 2024 | 25.27 Mn |
| Apr 30, 2024 | 28.04 Mn |
| Jan 31, 2024 | 28.85 Mn |
| Oct 31, 2023 | 28.20 Mn |
| Jul 31, 2023 | 28.00 Mn |
| Apr 30, 2023 | 29.68 Mn |
| Jan 31, 2023 | 29.09 Mn |
| Oct 31, 2022 | 27.19 Mn |
| Jul 31, 2022 | 25.41 Mn |
| Apr 30, 2022 | 26.28 Mn |
| Jan 31, 2022 | 24.35 Mn |
| Oct 31, 2021 | 21.23 Mn |
| Jul 31, 2021 | 20.57 Mn |